Business Context and Reporting Period
Kiora Pharmaceuticals, Inc. (KPRX) filed a Form 8-K Current Report on January 3, 2023, covering the event date of January 1, 2023. The registrant is a Delaware corporation listed on The Nasdaq Capital Market and is classified as an emerging growth company.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a corporate administrative change rather than a periodic financial report.
Material Changes
Effective January 1, 2023, the Company relocated its corporate headquarters. The new address is 332 Encinitas Boulevard, Suite 102, Encinitas, California 92024. The previous address was 1371 East 2100 South, Suite 200, Salt Lake City, Utah 84105. The Company's telephone number remains unchanged at (781) 788-9043.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The report is limited strictly to the notification of the change in principal executive office location.
Key Facts for Investors
- Corporate headquarters moved from Salt Lake City, Utah, to Encinitas, California, effective January 1, 2023.
- The Company's contact telephone number remains (781) 788-9043.
- No financial performance data or strategic updates are included in this specific filing.